Arrowhead Corp (ARWR) - Koefisien utang jangka dawa marang modal

Arrowhead Pharmaceuticals (ARWR) generates revenue through royalties and licensing fees from global pharma behemoths for access to its unique technologies. The company invests heavily in R&D to create systems for the targeted suppression of pathological genes. This price chart on the GURU.Markets platform, where the metric stands at 2.88, reflects the dynamics of a business developing revolutionary liver treatments by "switching off" diseases at the genetic level.

Leveraging an organic growth strategy and licensing agreements with pharma behemoths, the current long-term debt-to-equity ratio reflects the financial stability of Arrowhead Pharmaceuticals (ARWR). This metric compares obligations with maturities exceeding one year against shareholders' equity, allowing investors to assess the degree of leverage: low values confirm a conservative approach to funding R&D without the risk of excessive credit burden.